Daryl Kaswinkel, MD
Ophthalmology · Columbus, OHNPI 1831159110
Payments from drug & device makers
Across 191 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$2K
- Mallinckrodt Hospital Products Inc.$794
- AbbVie$679
- Lombart Brothers, Inc.$221
- Aerie Pharmaceuticals, Inc.$217
- Alcon$208
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$3,57663%
- Education$1002%
- Gifts$1,96535%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 1 | $1,920 |
| Mallinckrodt Hospital Products Inc. | 34 | $794 |
| AbbVie(2 entities) | 40 | $679 |
| Lombart Brothers, Inc. | 5 | $221 |
| Aerie Pharmaceuticals, Inc. | 16 | $217 |
| Alcon | 10 | $208 |
| Sun Pharmaceutical Industries Inc. | 8 | $178 |
| Novartis | 8 | $169 |
| Dompe US, Inc. | 9 | $152 |
| Tarsus Pharmaceuticals, Inc. | 6 | $151 |
| Mallinckrodt Enterprises LLC | 6 | $133 |
| Bausch & Lomb Americas Inc. | 6 | $128 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $108 |
| Biotissue Holdings Inc. | 5 | $102 |
| Kala Pharmaceuticals, Inc. | 6 | $89 |
| Amgen | 5 | $88 |
| Rxsight Inc | 2 | $64 |
| Glaukos Corporation | 3 | $57 |
| Oyster Point Pharma, Inc. | 3 | $51 |
| Harrow Eye, LLC | 2 | $42 |
| Shire North American Group Inc | 2 | $28 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $24 |
| Thea Pharma Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Ivantis, Inc | 1 | $13 |
| Sight Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- .9mm straight phaco tip$1,920
- ACTHAR$250
How this compares
$5,680 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 19 | $622,252 |
| RestasisCyclosporine | 97 | $122,932 |
| XiidraLifitegrast | 86 | $102,940 |
| LumiganBimatoprost | 77 | $36,472 |
| XdemvyLotilaner | 18 | $35,096 |
| CombiganBrimonidine Tartrate/Timolol | 90 | $32,306 |
| VyzultaLatanoprostene Bunod | 53 | $29,234 |
| RhopressaNetarsudil Mesylate | 51 | $28,888 |
| RocklatanNetarsudil Mesylat/Latanoprost | 46 | $26,831 |
| Alphagan PBrimonidine Tartrate | 38 | $18,675 |
| TyrvayaVarenicline Tartrate | 17 | $13,359 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 44 | $11,530 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 72 | $10,604 |
| Prednisolone Acetate | 241 | $8,503 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 189 | $7,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $152 | $622,25219 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $679 | $210,386302 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Zirgan | $128 | $138,038152 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $217 | $55,71997 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $151 | $35,09618 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $51 | $13,35917 claims |
| AlconSimbrinza | $208 | $11,53044 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $108 | $2,65217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Columbus
- David RogersColumbus$1.5M
- Alice EpitropoulosColumbus$702K
- Steven KatzColumbus$256K
- David LehmannColumbus$58K
- Lisa BorkowskiColumbus$25K
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.